Abstract
The mortality of critically ill patients with severe sepsis or septic shock has remained high despite different therapeutic innovations, the early and appropriate use of resuscitation measures, antimicrobial therapy adjusted to guidelines, and strict application of therapeutic packages at different admission times or patient diagnosis. The use of immunomodulation has been controversial in recent years, with international protocols and various literature reviews. However new studies on the use of immunoglobulin G enriched immunoglobulin M and A (IgA) have revived the debate. A current review of the pros, cons, and optimal use of enriched immunoglobulin G immunoglobulin M is presented.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
